The Cambridge-MIT Institute (CMI) is today launching a new initiative to unite biologists and medical researchers with physicists, engineers, computer scientists and mathematicians to work on an innovative approach to discovering the next generation of drugs.
CMI is funding a transatlantic Next-Generation Drug Discovery Community that will bring together researchers at Cambridge University and the Massachusetts Institute of Technology (MIT) with partners from the IT, pharmaceutical and biotechnology industries. They will be working on new methods of tackling the urgent and severe bottlenecks in the discovery and development of new drugs - particularly drugs for diseases with complex causes such as cancers, arthritis, multiple sclerosis, and diabetes.
Drug discovery is currently an extremely lengthy and costly process. On average, it takes new treatments $800m and twelve years to reach the market - and those are just the ones that succeed. But the sequencing of the human genome has made available a vast array of information about the many, very complex ways in which the human body works.
“Our aims are to develop safer and more effective new drugs, faster and cheaper,” says Professor Lauffenburger from MIT. “Another aim of this Community is reduce the current reliance on animal experiments to predict effects on humans.”
As part of its work, the Community is conducting two research projects. One is studying adult, blood stem cells with the aim of using them to establish new experimental systems to test the efficacy and toxicity of drugs on human physiology. The other project aims to establish new, computational methods by which drug targets can be identified from human gene- and protein-level data.
“There are major computational challenges involved,” says Dr Gos Micklem, who is part of the Cambridge team, “if we are going to make sense of all the data, and use it to start building systems-level views of life and disease processes. As we start to do this, and take into account the genetic variation between individuals, this opens up new possibilities in evaluating disease susceptibility, improved diagnosis and the ability to offer therapy tailored to each individual patient.”
The Next-Generation Drug Discovery Community is one of several new Knowledge Integration Communities (KICs) that the Cambridge-MIT Institute is setting up. These KICs aim to find new ways in which academia and industry can work together and exchange knowledge to push forward research in areas where UK industry has a demonstrable competitive position – like biotechnology and information technology . So alongside the research work, there are other strands to the Community. New educational programmes are being created. These include a new Masters degree programme at the University of Cambridge, an MPhil in Computational Biology, to teach biology to mathematicians and others, and make biologists more familiar with computer science.
Meanwhile, industry is also being informed about this work, and encouraged to join the Community.
Dr Adriano Henney, Director in Global Sciences & Information at AstraZeneca, says, “AstraZeneca, through its collaboration with MIT, already recognises the potential value of systems biology and mathematical modelling. During this collaboration, the joint project teams have prototyped the use of these approaches in drug discovery and this has helped to influence investment in the creation of a new, multidisciplinary capability in this area within the Company. We are looking forward to continuing our close collaboration with Professor Lauffenburger, and to the possibility of extending this to include Cambridge in the near future.”
Lize King | alfa
New dental implant with built-in reservoir reduces risk of infections
18.01.2017 | KU Leuven
Many muons: Imaging the underground with help from the cosmos
19.12.2016 | DOE/Pacific Northwest National Laboratory
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences